Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients
- Journal
- Nature Medicine
In The Last Decade
doi.org/10.1038/nm0796-811 →Countries where authors are citing Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients
This map shows the geographic impact of Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients more than expected).
Fields of papers citing Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients
This network shows the impact of Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients.
About Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients
This paper, published in 1996, received 608 indexed citations . Written by Turid Aas, Anne‐Lise Børresen, Stephanie Geisler, Birgitte Smith‐Sørensen, Hilde Johnsen, Jan Erik Varhaug, Lars A. Akslen and Per Eystein Lønning covering the research area of Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. It is primarily cited by scholars working on Oncology (446 citations), Molecular Biology (339 citations) and Cancer Research (238 citations). Published in Nature Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
This paper is also available at doi.org/10.1038/nm0796-811.